Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.
A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors pembrolizumab, atezolizumab, and cemiplimab in CSCC, followed by a focused discussion of recent cemiplimab trial data.
Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.
Shared insight on the use of immune checkpoint inhibitors in other patient populations within the skin cancer paradigm, and how lessons may be applied to patients with CSCC.